Harmonizing Pharmaceutical Regulation Among the United States, the European Union, and Japan: The ICH Initiative

DSpace/Manakin Repository

Harmonizing Pharmaceutical Regulation Among the United States, the European Union, and Japan: The ICH Initiative

Show simple item record

dc.contributor.advisor Hutt, Peter Barton en_US
dc.contributor.author Fayad, Nihal en_US
dc.date.accessioned 2012-06-07T20:36:16Z
dc.date.issued 2003 en_US
dc.identifier.citation Harmonizing Pharmaceutical Regulation Among the United States, the European Union, and Japan: The ICH Initiative (2003 Third Year Paper) en
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:8852171
dc.description.abstract The United States, the European Union and Japan comprise 75% of the world's pharmaceutical market and generate 90% of all pharmaceutical research. Recognizing the need for and benefits of harmonized testing standards the United States, the European Union and Japan formed a joint initiative between the industry and regulators called the International Conference on Harmonization (ICH). The ICH initiative has been underway for over a decade now. This paper will examine the disparate pharmaceutical regulatory regimes of the U.S., the EU, and Japan and will explore the ICH effort and its progress thus far. Part I of this paper overviews the current regulation of new pharmaceuticals in the United States, the European Union, and Japan. Based on these overviews, it will be apparent that the regulatory agencies of these three regions have already made some progress in harmonizing international standards. Part II explores the forces at work behind harmonization and discusses the potential benefits of pharmaceutical harmonization. Part III explains the ICH initiative including the mechanics of the ICH process and its implementation in the three ICH regions. Part IV of the paper addresses problems inherent in, and barriers to the achievement of the goals of the ICH. Finally, Part V of the paper discusses the accomplishments of the ICH thus far and evaluates its impact on the drug review process. en
dc.language.iso en_US en
dash.license LAA en_US
dc.subject Food and Drug Law en
dc.subject drug en
dc.subject approval en
dc.subject ICH en
dc.subject Harmonization en
dc.subject pharmaceutical regulation en
dc.title Harmonizing Pharmaceutical Regulation Among the United States, the European Union, and Japan: The ICH Initiative en
dc.type Paper (for course/seminar/workshop) en_US
dc.date.available 2012-06-07T20:36:16Z

Files in this item

Files Size Format View
Fayad.pdf 264.9Kb PDF View/Open
Fayad.rtf 245.5Kb RTF file View/Open
Fayad.html 198.8Kb HTML View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters